Skip to main content
Premium Trial:

Request an Annual Quote

Will a Clontech Sale Affect How -- and to Whom -- GFP is Sold?

Premium

An interesting aside to BD’s planned sale of Clontech is how it might affect the licensing minefield that is GFP — or more specifically, GFP from the jellyfish Aequoria victoria (AvGFP).

In June, Sian Godwin, GE Healthcare’s product manager for cellular analysis reagents, told Inside Bioassays that GFP is commercially available from Clontech, but in order to purchase it, for-profit organizations must first either take out a license from GE Healthcare, or they must have already had a license with the former Amersham Biosciences. Non-profit organizations are not required to obtain a license for GFP-based research, he said.

Helen Longvill, a PR manager with GE Healthcare’s biosciences division, further clarified this arrangement, and described how it might be affected by a Clontech sale.

“Clontech [has] the rights to sell GFP vectors to not-for-profit organizations — for example, academia — without restriction,” Longvill wrote in an email to Inside Bioassays last week. “Sales for commercial organizations can only be made to companies that GE Healthcare has licensed under the Aurora and BioImage Aequoria victoria GFP patent suites.”

In addition, the purchase of a license from GE Healthcare enables the sub-licensee to buy products from other licensed vendors, including Clontech, Longvill added. “We do not see this situation changing after the sale of Clontech, as any purchaser would inherit the same obligations,” she wrote.

It’s possible, then, that BD Biosciences would have to license the rights to AvGFP from GE Healthcare. Therefore, a more salient question regarding BD’s planned transition is whether this situation might affect its ability to conduct cell-based assays on its flow or imaging platforms.

According to Gene Vivino, vice president of strategic planning and portfolio management for BD Biosciences, it should minimally affect the company because it has a number of reagents in its portfolio to enable its increased cellular analysis aspirations.

“It’s too early to say what the final agreement might look like on the Clontech sale — what we might retain, and what we might not — in terms of technology and asset rights,” Vivino said. “Separately, we have our own technologies that are fully compatible with flow that we own the intellectual property on — similar, but different technologies. If we want to do cellular analysis applications with GFP, for example, our intent is not to constrain ourselves in that area.”

—BB

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.